Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials
Authors:
- Bryam López TuestaBTBryam López Tuesta
- Camila A. Arones-SantayanaCACamila A. Arones-Santayana
- Gustavo A. Valderrama SáenzGSGustavo A. Valderrama Sáenz
- Yerson Alberca-NairaYerson Alberca-Naira
- Hector I. Cedillo TorresHTHector I. Cedillo Torres
- Abdias Baltazar CastellanosACAbdias Baltazar Castellanos
- Daniel B. Müller QuintanillaDQDaniel B. Müller Quintanilla
- Judith Yangali-VicenteJYJudith Yangali-Vicente
- Joshuan J. BarbozaJBJoshuan J. Barboza
Open Access
- 21 March 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2157
Abstract
Introduction: Impetigo is a relatively common superficial infection of the skin and soft tissues. Although its prevalence is more significant in childhood, it might also occur in adulthood, affecting the quality of life of our patients. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ozenoxacin 1% with placebo or mupirocin was conducted. Databases searched included PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model, and heterogeneity was assessed using I2 statistics. Results: Four RCTs with 754 patients met the inclusion criteria. Ozenoxacin significantly improved the clinical success (RR: 1.14, 95% CI: 1.04–1.26, and I2 = 0%) and reduced the clinical failure (RR: 0.54, 95% CI: 0.39–0.75, and I2 = 0%) compared to the placebo. Microbiological success was also superior (RR: 1.31, 95% CI: 1.05–1.58, and I2 = 4%), while the microbiological failure was significantly lower (RR: 0.31, 95% CI: 0.21–0.46, and I2 = 0%). Comparisons with mupirocin showed similar efficacy, though the estimates were less precise. Conclusions: Ozenoxacin 1% is an effective treatment for impetigo, significantly improving clinical and microbiological outcomes while reducing the failure rates compared to the placebo. Its efficacy is comparable to mupirocin, suggesting it as a viable alternative for first-line therapy. Given the low heterogeneity observed, these findings support the clinical use of ozenoxacin for impetigo management. Future large-scale RCTs and direct comparative studies are warranted to further validate its therapeutic benefits.Keywords
Funding Information
- Universidad Inca Gargilazo de la Vega–Vicerrectorado de investigacion
- Universidad Señor de Sipán
This publication has 18 references indexed in Scilit:
- Enfrentamiento de las infecciones de piel en el adultoRevista Médica Clínica Las Condes, 2021
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigoInternational Journal of Women's Dermatology, 2020
- Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and AdolescentsDermatology, 2020
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With ImpetigoJAMA Dermatology, 2018
- Isolation of Bacillus simplex strain from Demodex folliculorum and observations about Demodicosis spinulosaClinical and Experimental Dermatology, 2016
- High Prevalence of Mupirocin Resistance in Staphylococcus aureus Isolates from a Pediatric PopulationAntimicrobial Agents and Chemotherapy, 2015
- GRADE guidelines: A new series of articles in the Journal of Clinical EpidemiologyJournal of Clinical Epidemiology, 2011
- In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxisJournal of Antimicrobial Chemotherapy, 2005
- Common skin infections in childrenBMJ, 2004